Short‐term study of infliximab treatment for Crohn's disease in China

OBJECTIVE:  To determine the effectiveness and safety of short‐term treatment of infliximab (IFX) in a group of Chinese patients with active Crohn's disease (CD).

[1]  Q. Ouyang,et al.  Progression of inflammatory bowel disease in China , 2010, Journal of digestive diseases.

[2]  J. Schölmerich.  Balancing the risks and benefits of prolonged use of infliximab , 2009, Gut.

[3]  Chun-li Zhou,et al.  Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China , 2008, Journal of digestive diseases.

[4]  F. Scaldaferri,et al.  Inflammatory bowel disease: Progress and current concepts of etiopathogenesis , 2007, Journal of digestive diseases.

[5]  中华医学会消化病学分会炎症性肠病协作组.  Chinese consensus on standard management of inflammatory bowel diseases(2007, Jinan) , 2007 .

[6]  P. Rutgeerts,et al.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.

[7]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[8]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[9]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[10]  L. Mayer.  Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohns disease (CD) , 2001 .

[11]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[12]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[13]  G. Porro,et al.  Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.

[14]  Province,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[15]  Province,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.